Home/ Stocks/ DSGN

Design Therapeutics, Inc. Common Stock

DSGN XNAS

$13.99 +0.22 (+1.60%) ▲ 15-min delayed

Open

$13.97

High

$14.17

Low

$13.65

Volume

418.9K

Market Cap

$861.75M

About Design Therapeutics, Inc. Common Stock

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 55 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-20,165,000	$-0.32
Q1 2026	$0	$-17,636,000	$-0.29
FY 2025	$0	$-69,792,000	$-1.22
Q3 2025	$0	$-16,997,000	$-0.30

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for DSGN yet. Check out our latest market news or earnings calendar.

Get DSGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Design Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.